title: Concurrent clarithromycin and cyclosporin A treatment.
abstract: Although macrolides have been associated with significant pharmacokinetic interactions, clarithromycin is considered to have a low interaction capacity. In this study, six transplant recipients treated with cyclosporin A also received clarithromycin. In all patients, the dose of cyclosporin A had to be reduced by a mean of 33% per day depending on the macrolide dose. Normalization of the dosage parameters began on the fourth day after stopping clarithromycin treatment. Co-administration of cyclosporin A and clarithromycin may lead to increases in whole blood cyclosporin levels, and appropriate dose reductions should be considered.
authors.affiliation: Clinical Pharmacology Department, University Clinic of Navarra School of Medicine, Pamplona, Spain. bsadaba@unav.es
authors.forename: B
authors.initials: B
authors.lastname: Sádaba
authors.forename: A
authors.initials: A
authors.lastname: López de Ocáriz
authors.forename: J R
authors.initials: JR
authors.lastname: Azanza
authors.forename: J
authors.initials: J
authors.lastname: Quiroga
authors.forename: J A
authors.initials: JA
authors.lastname: Cienfuegos
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D017291:Clarithromycin / Q000494:pharmacology*; D016572:Cyclosporine / Q000097:blood / Q000493:pharmacokinetics*; D004347:Drug Interactions; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics*; D016031:Liver Transplantation
chemical_list: D000900:Anti-Bacterial Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D017291:Clarithromycin